|Day Low/High||16.89 / 17.31|
|52 Wk Low/High||16.81 / 53.96|
I am working incrementally into some small stocks with great long-term value.
For his 'Executive Decision' segment, Cramer again sat down with Joe Papa, chairman and CEO of Valeant
Jim Cramer is bullish on PayPal, Marriott International, Randgold Resources, and Kirkland Lake.
Jim Cramer says despite chaos in Washington, the market's not falling. Why? Because stocks aren't a referendum on the presidency.
Joe Papa, chairman and CEO of Valeant Pharmaceuticals International, talks to Jim Cramer about his company's turnaround.
Domestic politics take the spotlight yet again
Citigroup cut its rating for the struggling generic drug maker to 'neutral'.
The drug stock deserved to go down, but the resulting selloff is an overreaction.
Jim Cramer likes International Paper and Inogen, but he's bearish on Teva Pharmaceuticals.
Jim Cramer says a well-diversified portfolio is a lot like a well-balanced and winning football team.
Teva just isn't 'the people's stock' it used to be.
Mylan execs have criticized the FDA, which they say has been too slow to approve competitors to complex drugs.
Teva's not the only one struggling to stay afloat in Israel.
Here's what you need to know now for Wed., Aug. 9.
Moody's kept Teva as investment grade because it remains the largest generic drug company in the world and still has strong cash flow.
If you want to reap big gains, read, understand and buy when the numbers make sense.
Teva receives special tax benefits from Israel.
Here's what you need to know now for Monday, Aug. 7.
Brent Saunders, chairman and CEO of Allergan, tells Jim Cramer he's bullish on new treatments for depression.
Jim Cramer says history doesn't have to repeat itself. You don't want to miss another opportunity in the highly visible FANG-style stocks.
It's time to trade some stocks.
RBC Capital analyst Randall Stanicky thinks Mylan is not immune to the broader challenges facing the generic drug industry.
Morgan Stanley doesn't have much confidence in Teva Pharmaceutical.
It's a long road to recovery for Teva, Morgan Stanley says.